{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04738981",
      "OrgStudyIdInfo": {
        "OrgStudyId": "GVHD-PKU2021"
      },
      "Organization": {
        "OrgFullName": "Peking University People's Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT",
      "OfficialTitle": "Efficacy and Safety of UC-MSCS for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT: A Multicenter, Randomized, Open-label Trial"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 1, 2021",
      "StudyFirstSubmitQCDate": "February 1, 2021",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 4, 2021",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "February 1, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 4, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Xiao Hui Zhang",
        "ResponsiblePartyInvestigatorTitle": "Vice president of Peking Univeristy Institute of Hematology",
        "ResponsiblePartyInvestigatorAffiliation": "Peking University People's Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Peking University People's Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Southern Medical University, China",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Third Military Medical University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Sun Yat-sen University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Randomized, open-label, multicenter study to investigate the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSC) for the treatment of steroid-resistant acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a view to establishing an effective treatment protocol for steroid-resistant aGVHD.",
      "DetailedDescription": "A total of 130 patients with steroid-resistant aGVHD after allo-HSCT are enrolled in this multicenter, randomized, controlled trial. Patients were randomized to UC-MSC + anti-CD25 monoclonal antibodies (mAb) group and anti-CD25 mAb group. The complete response (CR) rate after 4 weeks of treatment in the two groups will be compared. Adverse events are also recorded throughout the study."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Graft Vs Host Disease"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "130",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "UC-MSC and anti-CD25 mAb",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: UC-MSC",
                "Drug: Anti-CD25 mAb"
              ]
            }
          },
          {
            "ArmGroupLabel": "Anti-CD25 mAb",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Anti-CD25 mAb"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "UC-MSC",
            "InterventionDescription": "UC-MSC, iv, 1×10^6 cells/kg, once a week, for 4 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "UC-MSC and anti-CD25 mAb"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Umbilical cord-derived mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Anti-CD25 mAb",
            "InterventionDescription": "Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Anti-CD25 mAb",
                "UC-MSC and anti-CD25 mAb"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Basiliximab"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Rate of complete remission",
            "PrimaryOutcomeDescription": "Complete remission of aGVHD related symptoms and indicators",
            "PrimaryOutcomeTimeFrame": "4 weeks after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeDescription": "The time from randomization to death for any reason ( the last follow-up time for missing patients; end date of follow-up for patients who are live at the end of the study).",
            "SecondaryOutcomeTimeFrame": "At the end of Week 4 / 8 / 12 / 24 / 52."
          },
          {
            "SecondaryOutcomeMeasure": "Rate of partial remission",
            "SecondaryOutcomeDescription": "improvement of aGVHD staging in one or more organs without progression in other organs",
            "SecondaryOutcomeTimeFrame": "4 weeks after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Infusion toxicity",
            "SecondaryOutcomeDescription": "Acute toxicity responses include impaired function of heart, kidney and liver",
            "SecondaryOutcomeTimeFrame": "From the beginning of to four hours after every infusion of UC-MSC"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n1.Confirmed diagnosed steroid-resistant aGVHD after allo-HSCT. 2. Neutrophile granulocyte (ANC) ≥ 0.5 x 10^9/L. 3. Creatinine below 2 times normal upper limit . 4. Willing and able to sign written informed consent.\n\nExclusion Criteria:\n\n- 1. Untoleratation of the treatment. 2. Primary disease are not effectively controlled or are progressing. 3. Active infection (Bacteria, fungi, viruses ). 4. Combined with dysfunction of multiple organ. 5. Female patients who are nursing or pregnant, or who contemplate pregnancy during the study period.\n\n6. Patients who are deemed unsuitable for the study by the investigator.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Xiaohui Zhang, doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+8613522338836",
            "CentralContactEMail": "zhangxh100@sina.com"
          },
          {
            "CentralContactName": "Xueyan Sun, doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+8615625074109",
            "CentralContactEMail": "ssnowyan@163.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Xiaohui Zhang, doctor",
            "OverallOfficialAffiliation": "Peking University People's Hospital, Peking University Insititute of Hematology",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Peking University Insititute of Hematology, Peking University People's Hospital",
            "LocationCity": "Beijing",
            "LocationState": "Beijing",
            "LocationZip": "100010",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Undecided"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000006086",
            "ConditionMeshTerm": "Graft vs Host Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M8341",
            "ConditionBrowseLeafName": "Graft vs Host Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2832",
            "ConditionBrowseLeafName": "Homologous Wasting Disease",
            "ConditionBrowseLeafAsFound": "Graft vs Host Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000077552",
            "InterventionMeshTerm": "Basiliximab"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M1830",
            "InterventionBrowseLeafName": "Basiliximab",
            "InterventionBrowseLeafAsFound": "Lupus Erythematosus",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}